A phase III trial of Imigliptin Dihydrochloride for the treatment of diabetes mellitus
Latest Information Update: 07 Jul 2016
At a glance
- Drugs Imigliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 07 Jul 2016 New trial record
- 29 Mar 2016 According to a Sihuan Pharmaceutical Holdings Group media release, application for the conduct of a phase II trial has been made to the China Food and Drug Administration (CFDA) and acceptance notice was received in September 2015. The on-site inspection has been completed on October 2015 and the approval is expected in a near term.